COMPOUND AS ADENOSINE A2A RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Russian patent published in 2025 - IPC C07D487/04 C07D498/04 C07D513/04 A61K31/519 A61K31/53 A61P29/00 A61P35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula 1

,

where if W₁ is O, then W₂ is CH; if W₁ is S, then W₂ is N; Z₁ is CH or N; Z₂ is C or N; Z₃ is N, O or S; and are each independently a single bond or a double bond (if is a double bond, is a single bond and if is a single bond, is a double bond communication); Q is CR₄ or N; R₁ is H or -CH₃; R₂ is H, R₃ is H or -La-Ra or R₂ and R₃ are linked to form a ring, where La is a single bond or C1-C3 alkylene, Ra is C1-C5 alkyl, C3-C6 cycloalkyl, (a and b are each independently equal to 2, W₃ is CH or N, W₄ is CH₂ or O, where if W₃ is CH, then W₄ is not CH₂) or phenyl, and if Ra is C1-C5 alkyl or phenyl, at least one of H can be substituted with -OH or C1-C5 alkoxy; ring formed by binding R₂ and R₃, is 4–6 membered N-containing heterocycloalkyl (where at least each H of the N-containing heterocycloalkyl can be independently substituted with C1-C5 alkyl or OH) or 7-membered N-containing spiro-heterocycloalkyl; R₄ is H or C1-C5 alkyl; R₅ is

(where n is 0 or 1 and R_c, R_d, R_e, R_f and R_g is each independently H or C1-C5 alkyl, but two are selected from R_c, R_d, R_e, R_f and R_g can be associated with formation CH₂ or CH₂-CH₂);

(where m and q are each independently equal to 1 or 2 and R₃ is H or halogen);

(where r_, s, t and u are each independently equal to 1 or 2);

in said R₅ L₁ is a single bond or C1-C3 alkylene; L₂ is a single bond, -C(=O)-, -C(=O)NH-, -C(=O)-N(C1-C5 alkyl)-, -C(=O)-NH(C1 -C5 alkylene)-, -S(=O)₂- or -S (= O)₂-(C1-C3 alkylene)-; R_h is H, C1-C5 alkyl, C1-C5 alkoxy, C1-C5 haloalkyl, halogen, C3-C6 cycloalkyl, phenoxy, phenyl, -(C1-C5 alkylene) -phenyl, -phenylene-O-(C1-C5 alkyl), -phenylene-C(=O), phenylene-piperazinyl, 4–6 membered heterocycloalkyl containing 1–3 heteroatoms from at least one selected from N, O and S, 5–10 membered heteroaryl containing 1–3 heteroatoms from at least one selected from N, O and S,

,

or -NR₆R₇; R₆ and R₇ is each independently C1-C5 alkyl or C1-C5 haloalkyl; and at least one H from R_h each can be independently substituted with C1-C5 alkyl, C1-C5 alkoxy, C1-C5 haloalkyl, OH or halogen, as well as to pharmaceutical compositions and use of the compounds as an adenosine receptor A2a antagonist.

EFFECT: novel compounds which can be used as an adenosine receptor A2a antagonist are obtained.

12 cl, 58 tbl, 54 ex